Newsmeme!
Discover News you didn't know existed
Titration
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Dublin City Council awards bicentennial funding
Published July 2, 2009, 10:42 am, This Week Dublin
Dublin City Council approved funding Wednesday night for six activities that will celebrate the city's bicentennial next year.
XenoPort Reports Positive Results From A Phase 2 Trial Of Arbaclofen Placarbil In Spinal Cord Injury Patients With ...
Published July 2, 2009, 7:08 am, Medical News Today
XenoPort, Inc. (Nasdaq:XNPT) announced positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil (AP), also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury (SCI). Doses of 20 and 30 mg of AP, given twice daily (BID), demonstrated statistically significant improvements compared to placebo for the primary endpoint of the study.
Reporting Software promotes data access, decision-making.
Published July 1, 2009, 5:52 am, ThomasNet
ClinPhone RTSM (Randomization and Trial Supply Management) technologies offer validated randomization methods, automated inventory control, dispensing/titration management, and emergency code break capabilities. It features Universal Report Suite to monitor trial management performance, RTSM Dashboard with trending/forecasting functionalities, and Self-Service Module with customizable search ...
XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients with ...
Published June 30, 2009, 3:30 am, Business Wire via Yahoo! Finance
SANTA CLARA, Calif.----XenoPort, Inc. announced today positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil , also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury .
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
Published June 29, 2009, 12:59 am, redOrbit
S.
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
Published June 28, 2009, 10:10 pm, ITNews
S. MAMEDE DO CORONADO, Portugal, June 29 /PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and sustained decrease in seizure frequency over the long-term(1).
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |